Researchers develop first inhibitors against key epigenetic complex involved in cancer

Activity of the polycomb repressive complex 1 is essential for the development and maintenance of leukemic cells; disrupting it presents a new potential therapeutic approach.

11:34 AM

Author | Ian Demsky

lime green structure with purple in left middle and lab note badge in navy and yellow in bottom right
Structure showing a PRC1 inhibitor developed at U-M in complex with the PRC1 RING domain.

Leukemia stem cells are rare cells that can renew themselves while continuing to generate malignant cells known as leukemic blasts. These cells are difficult to eradicate using chemotherapy drugs and frequently lead to recurrence of leukemia.

Leukemia stem cells, however, are dependent on a protein complex called polycomb repressive complex 1, or PRC1, which interacts with chromatin and turns genes off.

Now a team of researchers led by Tomasz Cierpicki, Ph.D., and Jolanta Grembecka, Ph.D., from the University of Michigan has developed the first small-molecule inhibitors of PRC1 — a first step toward developing a potential new therapeutic approach to treating acute myeloid leukemia by shutting down the activity of leukemia stem cells.

These inhibitors demonstrate activity in leukemia cells and patient samples, as reported in Nature Chemical Biology, and also open new opportunities to study the development of leukemia at the molecular level.

"Our lead compound, RB-3, represents an attractive and unique agent for studying PRC1 biology," said Cierpicki, an associate professor of biophysics and pathology at U-M. "This work demonstrates that directly targeting the activity of PRC1 is indeed feasible and could lay the groundwork for the development of new pharmaceutical agents for leukemia and possibly other cancers."

The study was a close collaboration between his lab and the lab of co-senior author Grembecka, an associate professor of pathology at Michigan Medicine and co-director of the developmental therapeutics program at the U-M Rogel Cancer Center.

Disclosure: The University of Michigan has applied for patent protection on the PRC1 inhibitors and several of the authors are listed as co-inventors.

Paper cited: "Small molecule inhibitors targeting Polycomb repressive complex 1 RING domain," Nature Chemical Biology. DOI: 10.1038/s41589-021-00815-5

More Articles About: Lab Notes Leukemia Basic Science and Laboratory Research Cancer Research Cancer: Cancer Types
Health Lab word mark overlaying blue cells
Health Lab

Explore a variety of healthcare news & stories by visiting the Health Lab home page for more articles.

Media Contact Public Relations

Department of Communication at Michigan Medicine

[email protected]


Stay Informed

Want top health & research news weekly? Sign up for Health Lab’s newsletters today!

Featured News & Stories protein in pink and blue an light grey with lab note badge spelled out on bottom right in yellow background and navy font
Health Lab
Researchers Develop First-in-Class Inhibitors Against Key Leukemia Protein
Approach opens a new avenue to study the biology of acute leukemia and for the development new drugs.
Health Lab
"Drawing Dad" becomes sensation throughout pediatric cancer unit
A form of art therapy for one dad brings joy to patients across his child's floor, also in-patient receiving treatments.
liver in bright green against navy background
Health Lab
Genetic variation with MASLD reveals subtypes and potential therapeutic avenues
A Michigan Medicine team of experts seeks to identify the human genetic causes of MASLD, formerly called NAFLD
cells colorful
Health Lab
Improvements in human genome databases offer a promising future for cancer research
A gene sequencing method called ribosome profiling has expanded our understanding of the human genome by identifying previously unknown protein coding regions. Also known as Ribo-seq, this method allows researchers to get a high-resolution snapshot of protein production in cells.
bacteria black background yellow cell
Health Lab
The surprising origin of a deadly hospital infection
Surprising findings from a Michigan Medicine study in Nature Medicine suggest that the burden of C. diff infection may be less a matter of hospital transmission and more a result of characteristics associated with the patients themselves.
flies moving sled in snow with person
Health Lab
Gene links exercise endurance, cold tolerance and cellular maintenance in flies
A study in PNAS identifies a protein that, when missing, makes exercising in the cold that much harder—that is, at least in fruit flies.